Innate Pharma (IPHA) Other Non-Current Liabilities (2017 - 2025)

Innate Pharma (IPHA) has disclosed Other Non-Current Liabilities for 8 consecutive years, with $292795.1 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Other Non-Current Liabilities fell 54.87% year-over-year to $292795.1, compared with a TTM value of $292795.1 through Dec 2024, down 54.87%, and an annual FY2024 reading of $296560.7, down 54.53% over the prior year.
  • Other Non-Current Liabilities was $292795.1 for Q4 2024 at Innate Pharma, down from $648791.8 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $648791.8 in Q4 2023 and bottomed at $202009.0 in Q4 2022.
  • Average Other Non-Current Liabilities over 5 years is $339303.3, with a median of $289424.7 recorded in 2021.
  • The sharpest move saw Other Non-Current Liabilities soared 221.17% in 2023, then plummeted 54.87% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $263496.1 in 2020, then grew by 9.84% to $289424.7 in 2021, then tumbled by 30.2% to $202009.0 in 2022, then skyrocketed by 221.17% to $648791.8 in 2023, then tumbled by 54.87% to $292795.1 in 2024.
  • Business Quant data shows Other Non-Current Liabilities for IPHA at $292795.1 in Q4 2024, $648791.8 in Q4 2023, and $202009.0 in Q4 2022.